Emily Visit 2: Fibromyalgia concomitant with rheumatoid arthritis
| Title: | Emily Visit 2: Fibromyalgia concomitant with rheumatoid arthritis |
| Topic: | Fibromyalgia |
| Relevant Terms: | Arthritis, Pain Management, Rheumatoid Arthritis |
| Primary Audience: | Primary Care Physicians, Rheumatologists |
| Launch Date: | 01-Mar-11 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | The accreditation for this activity has expired. |
| Curriculum Name: | Optimal Management of Fibromyalgia: A Virtual Patient Educational Experience |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Discuss details of current approaches used to diagnose fibromyalgia
- Integrate recent evidence supporting the use of specific pharmacologic agents in the treatment of fibromyalgia to improve patient outcomes
- Incorporate the most appropriate nonpharmacologic interventions for the treatment of patients with fibromyalgia to further improve individualized treatment plans
Faculty
Philip J. Mease, MD
Director of Rheumatology Research
Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington
Kurt Kroenke, MD
Director of Fellowship and Training Programs and Research Scientist
Regenstrief Institute, Inc.
Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana
Kim Jones, RN, FNP, PhD
Associate Professor
Oregon Health & Science University School of Nursing Portland Campus
Portland, Oregon
Director of Rheumatology Research
Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington
Kurt Kroenke, MDDirector of Fellowship and Training Programs and Research Scientist
Regenstrief Institute, Inc.
Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana
Kim Jones, RN, FNP, PhDAssociate Professor
Oregon Health & Science University School of Nursing Portland Campus
Portland, Oregon
INSTRUCTIONS FOR OBTAINING CME CREDIT
There are no fees or prerequisites for participating in and receiving CME credit for this online educational activity. In order to obtain CME credit for participating in this activity during the period of March 1, 2011, through March 1, 2012, participants must (1) read the educational objectives and disclosure statements; (2) participate in the educational activity; (3) complete the online learning assessment, scoring 50% or higher; (4) complete the evaluation; and (5) submit the evaluation form online which will take up to 0.50 hr.
A statement of credit will be issued only upon completion of a post-test with a score of 50% or higher and a completed activity evaluation. After submitting these forms, you will be able to print out your CME certificate.
Statement of Need
The primary care clinician is emerging as the key individual to manage patients with fibromyalgia. While diagnostic accuracy and treatment regimens are being chosen with increasing accuracy, gaps in performance are still prevalent. Inappropriate diagnosis of fibromyalgia occurs in approximately 30% of all patients managed by primary care clinicians and up to 65% of patients are prescribed medications with little or no evidence supporting their efficacy in ameliorating fibromyalgia-related symptoms. It is important that clinicians receive a better grounding in important clues to help them diagnose fibromyalgia with more accuracy and treat patients — both with pharmacologic and nonpharmacologic agents — more effectively.
Disclosure
There are no fees or prerequisites for participating in and receiving CME credit for this online educational activity. In order to obtain CME credit for participating in this activity during the period of March 1, 2011, through March 1, 2012, participants must (1) read the educational objectives and disclosure statements; (2) participate in the educational activity; (3) complete the online learning assessment, scoring 50% or higher; (4) complete the evaluation; and (5) submit the evaluation form online which will take up to 0.50 hr.
A statement of credit will be issued only upon completion of a post-test with a score of 50% or higher and a completed activity evaluation. After submitting these forms, you will be able to print out your CME certificate.
University of Michigan Accreditation Statement
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this enduring material for a maximum of 0.50 credits AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Statement of Need
The primary care clinician is emerging as the key individual to manage patients with fibromyalgia. While diagnostic accuracy and treatment regimens are being chosen with increasing accuracy, gaps in performance are still prevalent. Inappropriate diagnosis of fibromyalgia occurs in approximately 30% of all patients managed by primary care clinicians and up to 65% of patients are prescribed medications with little or no evidence supporting their efficacy in ameliorating fibromyalgia-related symptoms. It is important that clinicians receive a better grounding in important clues to help them diagnose fibromyalgia with more accuracy and treat patients — both with pharmacologic and nonpharmacologic agents — more effectively.
It is the policy of the University of Michigan Medical School that the education presented within the University of Michigan Medical School provided, CME-certified activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, the University of Michigan Medical School provides information that planners, teachers, authors, developers, and activity managers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Any relationships that an individual may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.
Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; S, Stock shareholder; SB, Speaker bureau; H, Honoraria; O, Other.
Educational Planning Committee
Philip J. Mease, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc., Crescendo Pharma, Genentech, Hoffman La-Roche, Sanofi-Aventis, UCB, Wyeth, Pfizer, Cypress Pharmaceuticals Inc., Forest Pharmaceuticals Inc., Eli Lilly and Company, Fralex Therapeutics Inc., Boehringer-Ingelheim, Jazz Pharmaceuticals, Allergan/A, C; Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc., Crescendo Pharma, Genentech, Hoffman La-Roche, Wyeth, Pfizer, Cypress Pharmaceuticals, Inc., Forest Pharmaceuticals Inc., Eli Lilly and Company, Fralex Therapeutics, Inc., Boehringer-Ingelheim, Jazz Pharmaceuticals, Allergan/G; Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc., Genentech, Wyeth, Pfizer, Cypress Pharmaceuticals Inc., Forest Pharmaceuticals Inc., Eli Lilly and Company/SB.
Kurt Kroenke, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Eli Lilly and Company, Forest Pharmaceuticals Inc./A, H.
Kurt Kroenke, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Eli Lilly and Company, Forest Pharmaceuticals Inc./A, H.
Kim Jones, MD, has disclosed the following relevant financial relationship that has occurred within the past 12 months: Jazz Pharmaceuticals/ A; Forest Pharmaceuticals Inc./G; Eli Lilly and Company, Pfizer, Forest Pharmaceuticals Inc./SB.
Kathy Holliman, Medical Writer, has disclosed that she has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
University of Michigan CME Content Reviewer
Daniel J. Clauw, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Pfizer, Eli Lilly and Company, Forest Pharmaceuticals, Inc., Cypress Pharmaceuticals, Inc., Biosciences, Pierre Fabre, UCB, Jazz Pharmaceuticals, Merck/C.
Activity Development Team
Cathy Pagano, CCMEP; Sandra Davidson; Christine M. O'Leary, PharmD, BCPS, CCMEP; Karen Thomas, CCMEP; Scott Kober, CCMEP; Courtney Cohen; Tina Chiu, MEd; and Melissa Schepacarter, CMP, are employees of the Institute for Continuing Healthcare Education and are collectively responsible for the planning, development, and management of this CME activity. These individuals have disclosed that they have had no relevant financial relationship specific to the subject matter of this activity that have occurred within the past 12 months. Shunda R. Irons-Brown, PhD, MBA, CCMEP also an employee of the Institute, has disclosed the following relationships: Merck & Co./S; Bristol-Myers Squibb, GlaxoSmithKline/O.
Product Disclosure
Commercial Support
The activity is sponsored by the University of Michigan Medical School
COURSE VIEWING REQUIREMENTS
For additional technical support, please send an email to tchiu@iche.edu
General Disclosure and Copyright
Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosage, and contraindications. This recommendation is particularly important with new or infrequently used products.
Kathy Holliman, Medical Writer, has disclosed that she has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
University of Michigan CME Content Reviewer
Daniel J. Clauw, MD
Professor of Anesthesiology
Professor of Internal Medicine (Rheumatology)
Director, Chronic Pain and Fatigue Research Center
Department of Anesthesiology
University of Michigan Medical School
Daniel J. Clauw, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Pfizer, Eli Lilly and Company, Forest Pharmaceuticals, Inc., Cypress Pharmaceuticals, Inc., Biosciences, Pierre Fabre, UCB, Jazz Pharmaceuticals, Merck/C.
Activity Development Team
Cathy Pagano, CCMEP; Sandra Davidson; Christine M. O'Leary, PharmD, BCPS, CCMEP; Karen Thomas, CCMEP; Scott Kober, CCMEP; Courtney Cohen; Tina Chiu, MEd; and Melissa Schepacarter, CMP, are employees of the Institute for Continuing Healthcare Education and are collectively responsible for the planning, development, and management of this CME activity. These individuals have disclosed that they have had no relevant financial relationship specific to the subject matter of this activity that have occurred within the past 12 months. Shunda R. Irons-Brown, PhD, MBA, CCMEP also an employee of the Institute, has disclosed the following relationships: Merck & Co./S; Bristol-Myers Squibb, GlaxoSmithKline/O.
Product Disclosure
There are no off-label and/or investigational uses discussed within this educational activity.
The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.
Commercial Support
Supported by an educational grant from Pfizer.
The activity is sponsored by the University of Michigan Medical School
COURSE VIEWING REQUIREMENTS
| PC Internet Explorer (v6 or greater), or Firefox |
MAC Safari |
For additional technical support, please send an email to tchiu@iche.edu
General Disclosure and Copyright
The opinions expressed in this educational activity are those of the participating faculty and not those of the Institute for Continuing Healthcare Education, Pfizer, or any manufacturers of products mentioned herein.
The information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional relative to diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute for Continuing Healthcare Education be responsible for any decision made or action taken based upon the information provided through this activity.
Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosage, and contraindications. This recommendation is particularly important with new or infrequently used products.
Copyright 2011, Institute for Continuing Healthcare Education. All rights reserved. No part of this presentation may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from the Institute.
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.
